ClinConnect ClinConnect Logo
Search / Trial NCT01829191

Controlling Myopia Progression With Soft Contact Lenses (Contact Lens Control)

Launched by JOHNSON & JOHNSON VISION CARE, INC. · Apr 8, 2013

Trial Information

Current as of April 30, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. The subject must be between 8 and 12 years of age.
  • 2. At least one of the subject's parents or legal guardian must read and understand English or Chinese.
  • 3. The subject's manifest objective refraction (measured with an auto refractor) must be sphere: between -0.25D and -4.50D, and cylinder: \<1.50D in each eye.
  • 4. The subject's best sphere contact lens correction must lie between -0.75D (better of the two eyes)and -4.25D (poorer of the two eyes).
  • 5. The subject's cycloplegic objective refraction must be here: between -0.75D and -4.00D cylinder: \< or equal to 1.00D in each eye.
  • 6. The subject must have 1.00D or less difference in spherical equivalent between the two eyes with cycloplegic refraction.
  • 7. The subject must have a spectacle lens best-corrected visual acuity of 0.8 (20/25) or better in both eyes.
  • 8. The subject's parent or legal guardian must read and sign the STAEMENT OF INFORMED CONSENT and the subject must read and sign the Child's Assent Form and be provided a copy of each form.
  • 9. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • Exclusion Criteria:
  • 1. Ocular or systemic allergies or diseases that may interfere with contact lens wear.
  • 2. Systemic disease or autoimmune disease or use of medications (e.g. antihistamine), which may interfere with contact lens wear.
  • 3. Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormality of the cornea, which may contraindicate contact lens wear.
  • 4. Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection that might interfere with contact lens wear.
  • 5. Any ocular infection.
  • 6. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • 7. Any infectious disease (e.g. hepatitis, tuberculosis) or an immunosuppressive disease (e.g. HIV)
  • 8. Diabetes
  • 9. Anisometropia of greater than 1.00D by cycloplegic refraction.
  • 10. Astigmatism of greater than 1.00D in either eye by cycloplegic refraction.
  • 11. Eye injury or surgery within eight weeks immediately prior to enrollment for this study.
  • 12. Previous refractive surgery, orthokeratology, keratoconus, or other corneal irregularity in either eye. Rigid contact lens wearers cannot be enrolled in the study unless they are off rigid contact lenses for at least 4 weeks.
  • 13. Strabismus in either eye.
  • 14. Pupil or lid abnormality or infection in either eye
  • 15. Central corneal scar in either eye
  • 16. Aphakia in either eye
  • 17. Contraindications to contact lens wear such as dry eye or history of prior unsuccessful contact lens wear.
  • 18. History of participation in prior clinical trials aimed to control myopia progression.
  • 19. Surgically altered eyes, ocular infection of any type, ocular inflammation.
  • 20. An anterior chamber angle grade 2 or narrower by the Van Herrick method

About Johnson & Johnson Vision Care, Inc.

Johnson & Johnson Vision Care, Inc. is a leading global company dedicated to advancing the field of eye health through innovative solutions and research. A subsidiary of Johnson & Johnson, it specializes in the development and manufacturing of contact lenses, surgical products, and vision correction technologies. With a commitment to improving the quality of life for individuals facing vision challenges, the company invests significantly in clinical trials and scientific research to ensure safety, efficacy, and optimal performance of its products. Johnson & Johnson Vision Care, Inc. is renowned for its robust portfolio that combines cutting-edge technology with a patient-centered approach, striving to enhance visual care for people around the world.

Locations

Boston, Massachusetts, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials